drugset / Trial / NCT03673215
The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics and pharmacodynamics of recombinant human thrombopoietin in the patients with different degree of liver function impairment according Child- Pugh class.
Timeline
- Start
- 2018-06-28
- Primary completion
- 2020-10-08
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | recombinant human thrombopoietin | Protein / enzyme biologic | 150 iu/kg | Subcutaneous |
| Subject | recombinant human thrombopoietin | Protein / enzyme biologic | 300 iu/kg | Subcutaneous |
| Subject | recombinant human thrombopoietin | Protein / enzyme biologic | 450 iu/kg | Subcutaneous |